One year later: living and breathing the green transition
The shift to low Global Warming Potential (GWP) propellants in pressurised Metered Dose Inhalers (pMDIs) is gaining momentum in the inhalation sector.
Combining decades of experience, next-generation capabilities and a network of expert partners, Bespak isn’t just leading the green transition –– we’re living and breathing it.
A year of progress
One year ago, Nick Atkinson, Bespak’s Head of Project Management, Drug Product Development explored how we were laying the groundwork to streamline the industry transition. Since then, we have established collaborations across the value chain, expanded our manufacturing capabilities for low GWP propellants, and brought our specialist expertise to bear.
This has enabled us to grow our understanding of manufacturing with the two new propellants. We have leveraged knowledge from other industries to inform how we prepare for next-generation, low GWP propellants across our organisation, and we have worked hard to use our unique skills and expertise to accelerate the transition across the industry.
Driving real industry change
Our efforts have been marked with real, impactful milestones.
Bespak is the first CDMO to offer commercial manufacturing capabilities for both low GWP propellants, HFA-152a and HFO-1234ze.
We played a pivotal role in the approval of the first pMDI using a low GWP propellant,Trixeo Aerosphere.
Our experts have taken seats on the boards of the International Pharmaceutical Aerosol Consortium (IPAC) and International Pharmaceutical Aerosol Consortium Regulation & Science (IPAC-RS).
We have optimised BK357, the world’s most trusted dosing valve, for low GWP propellants.
Are you ready?
We are proud of all that we have achieved and look forward to further progress as we continue to drive the green transition from fantasy to reality. If you are considering embarking on a low carbon pMDI project, we are here to help. Get in touch to discuss how we can streamline your product’s journey to market.
